(Q36840621)

16 August 2017

1 reference

title

The clinical role of genetic polymorphisms in drug-metabolizing enzymes (English)

1 reference

16 August 2017

Tomalik-Scharte D

1

1 reference

16 August 2017

Lazar A

series ordinal

2

1 reference

16 August 2017

Fuhr U

series ordinal

3

1 reference

16 August 2017

Kirchheiner J

series ordinal

4

1 reference

16 August 2017

publication date

5 June 2007

1 reference

The Pharmacogenomics Journal

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

4-15

1 reference

Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

Defective metabolism of metoprolol in poor hydroxylators of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

CYP2C19 polymorphism and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

[The value of pharmacogenetic tests in antidepressive medication therapy].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Some aspects of genetic polymorphism in the biotransformation of antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Non-linear fluvoxamine disposition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Venlafaxine serum levels and CYP2D6 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The role of cytochrome P450 2D6 in the metabolism of moclobemide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Oxidation phenotype--a major determinant of metoprolol metabolism and response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Stereoselective disposition of carvedilol is determined by CYP2D6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C9*1/*3 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics of acenocoumarol pharmacodynamics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Acenocoumarol stabilization is delayed in CYP2C93 carriers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Determination of bleeding risk using genetic markers in patients taking phenprocoumon

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics of the proton pump inhibitors: a systematic review.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenomics of proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The CYP2C19 enzyme polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Therapeutic drug monitoring of antimetabolic cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Known variant DPYD alleles do not explain DPD deficiency in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics of the human arylamine N-acetyltransferases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Genetically determined variability in acetylation and oxidation. Therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500462

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500462

1 reference

16 August 2017

1 reference